Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1988 Mar;32(3):354–357. doi: 10.1128/aac.32.3.354

Pharmacokinetics of carumonam after single and multiple 1- and 2-g dosage regimens.

D Bérubé 1, F Vallée 1, A C Panneton 1, M G Bergeron 1, M LeBel 1
PMCID: PMC172175  PMID: 3364953

Abstract

The pharmacokinetics of carumonam after single and multiple intravenous administration of 1- and 2-g dosage regimens were studied in 12 young male volunteers. Plasma and urine samples were collected in serial order for 24 h and assayed by high-pressure liquid chromatography. The mean elimination half-life of carumonam was not significantly affected by either dosage regimen or single dose versus steady state, ranging from 1.3 to 1.5 h. Mean concentrations at the end of the interval were not influenced by a multiple-dose administration. The normalized volume of distribution was independent of the dose, with values ranging from 0.16 to 0.19 liters/kg. After multiple administration, carumonam was cleared from the body more rapidly: from 96.2 to 121.7 ml/min after 1 g every 8 h, and from 102.1 to 122.3 ml/min after 2 g every 8 h (P less than 0.05). After 24 h, 75.0 to 80.7% of the dose was excreted unchanged in the urine. The protein binding of carumonam to human plasma remained stable at 28%. Carumonam was well tolerated by the volunteers.

Full text

PDF
354

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Angehrn P. Antibacterial properties of carumonam (Ro 17-2301, AMA-1080), a new sulfonated monocyclic beta-lactam antibiotic. Chemotherapy. 1985;31(6):440–450. doi: 10.1159/000238372. [DOI] [PubMed] [Google Scholar]
  2. Arvidsson A., Borgå O., Alván G. Renal excretion of cephapirin and cephaloridine: evidence for saturable tubular reabsorption. Clin Pharmacol Ther. 1979 Jun;25(6):870–876. doi: 10.1002/cpt1979256870. [DOI] [PubMed] [Google Scholar]
  3. Egger H. J., Fischer G. Determination of the monocyclic beta-lactam antibiotic carumonam in plasma and urine by ion-pair and ion-suppression reversed-phase high-performance liquid chromatography. J Chromatogr. 1987 Sep 25;420(2):357–372. doi: 10.1016/0378-4347(87)80191-3. [DOI] [PubMed] [Google Scholar]
  4. Horber F., Egger H. J., Weidekamm E., Dubach U. C., Frey F. J., Probst P. J., Stoeckel K. Pharmacokinetics of carumonam in patients with renal insufficiency. Antimicrob Agents Chemother. 1986 Jan;29(1):116–121. doi: 10.1128/aac.29.1.116. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Imada A., Kondo M., Okonogi K., Yukishige K., Kuno M. In vitro and in vivo antibacterial activities of carumonam (AMA-1080), a new N-sulfonated monocyclic beta-lactam antibiotic. Antimicrob Agents Chemother. 1985 May;27(5):821–827. doi: 10.1128/aac.27.5.821. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Koeppe P., Höffler D., Strobel K. Pharmacokinetics and dose recommendations of carumonam in renal failure. Arzneimittelforschung. 1987 Jan;37(1):65–69. [PubMed] [Google Scholar]
  7. Le Blanc P. P., Dumas J. Calcul des valeurs initiales des paramètres pharmacocinétiques à l'aide d'un calculateur programmable. Therapie. 1983 Jan-Feb;38(1):21–26. [PubMed] [Google Scholar]
  8. McNulty C. A., Garden G. M., Ashby J., Wise R. Pharmacokinetics and tissue penetration of carumonam, a new synthetic monobactam. Antimicrob Agents Chemother. 1985 Sep;28(3):425–427. doi: 10.1128/aac.28.3.425. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Neu H. C. Antibiotics in the second half of the 1980s. Areas of future development and the effect of new agents on aminoglycoside use. Am J Med. 1986 Jun 30;80(6B):195–203. doi: 10.1016/0002-9343(86)90501-2. [DOI] [PubMed] [Google Scholar]
  10. Neu H. C., Chin N. X., Labthavikul P. The in-vitro activity and beta-lactamase stability of carumonam. J Antimicrob Chemother. 1986 Jul;18(1):35–44. doi: 10.1093/jac/18.1.35. [DOI] [PubMed] [Google Scholar]
  11. Perrier D., Mayersohn M. Noncompartmental determination of the steady-state volume of distribution for any mode of administration. J Pharm Sci. 1982 Mar;71(3):372–373. doi: 10.1002/jps.2600710332. [DOI] [PubMed] [Google Scholar]
  12. Smith I. L., Schentag J. J. Noncompartmental determination of the steady-state volume of distribution during multiple dosing. J Pharm Sci. 1984 Feb;73(2):281–282. doi: 10.1002/jps.2600730239. [DOI] [PubMed] [Google Scholar]
  13. Swabb E. A., Sugerman A. A., McKinstry D. N. Multiple-dose pharmacokinetics of the monobactam azthreonam (SQ 26,776) in healthy subjects. Antimicrob Agents Chemother. 1983 Jan;23(1):125–132. doi: 10.1128/aac.23.1.125. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Swabb E. A., Sugerman A. A. Review of single- and multiple-dose pharmacokinetics of the monobactam, aztreonam (SQ 26,776) in healthy subjects. Chemotherapy. 1983;29(5):313–321. doi: 10.1159/000238214. [DOI] [PubMed] [Google Scholar]
  15. Weidekamm E., Stoeckel K., Egger H. J., Ziegler W. H. Single-dose pharmacokinetics of Ro 17-2301 (AMA-1080), a monocyclic beta-lactam, in humans. Antimicrob Agents Chemother. 1984 Dec;26(6):898–902. doi: 10.1128/aac.26.6.898. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Wilkinson G. R. Clearance approaches in pharmacology. Pharmacol Rev. 1987 Mar;39(1):1–47. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES